This study evaluated the impact of adding the oral HCV NS@/@A protease inhibitor simeprevir to PR on patient-reported fatigue and health status among patients with chronic HCV genotype @ infection enrolled in the Phase IIb PILLAR and ASPIRE trials -LSB- NCT@ ; NCT@ -RSB- .